- Home
- RPRX
RPRX
Royalty Pharma plc
as 10-07-2025 3:29pm EST
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 15.6B | IPO Year: | 2020 |
| Target Price: | $44.50 | AVG Volume (30 days): | 5.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 2.32 | EPS Growth: | 54.86 |
| 52 Week Low/High: | $24.05 - $38.00 | Next Earning Date: | 11-05-2025 |
| Revenue: | $2,305,243,000 | Revenue Growth: | 3.02% |
| Revenue Growth (this year): | 35.14% | Revenue Growth (next year): | 1.24% |
Stock Insider Trading Activity of Royalty Pharma plc (RPRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Norden Gregory | RPRX | N/A | Aug 11 '25 | Sell | $36.23 | 33,500 | $1,213,748.55 | 194,848 |
Latest Royalty Pharma plc News
RPRX Breaking Stock News: Dive into RPRX Ticker-Specific Updates for Smart Investing
Insider Monkey
6 days ago
Revolution Medicines, Inc. (RVMD) Insider Sells Shares
GlobeNewswire
18 days ago
Royalty Pharma to Present at Bernstein’s 2nd Annual Healthcare Forum
Insider Monkey
20 days ago
TD Cowen Maintains a Buy on Royalty Pharma (RPRX)
StockStory
21 days ago
1 Safe-and-Steady Stock with Promising Prospects and 2 We Ignore
Insider Monkey
22 days ago
Royalty Pharma plc (RPRX) Reports 20% Portfolio Growth, Posts $727M in Q2 Receipts
Insider Monkey
a month ago
Royalty Pharma plc (RPRX) Commits $300M to Zenas’ Obexelimab Program
GlobeNewswire
a month ago
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
GlobeNewswire
a month ago
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
Compare RPRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RPRX Royalty Pharma plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.